|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
: Our findings suggest that there is a link between the p53 dependent cell cycle arrest and γ-H2AX dependent DNA repair pathway in endometrial cancer.
|
21185067 |
2011 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
|
8687148 |
1996 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Endometrial carcinoma associated with hyperplasia--immunohistochemical study of angiogenesis and p53 expression.
|
9889029 |
1999 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
TP53 mutation (and associated p53 protein overexpression) is probably a negative prognostic marker in endometrial cancers, but its relevance in the rarer histologic subtypes, including clear cell carcinomas, has not been delineated.
|
23524907 |
2013 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
TP53 was silenced in two endometrial cancer cell lines to study its effect on p21 and p63.
|
28511869 |
2017 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A high frequency of allelic losses corresponding to the 17p13.3 region that contained the p53 gene sequence was also noted in human endometrial carcinoma.
|
8473053 |
1993 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.
|
17119852 |
2007 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
A simple combination of morphological and immunohistochemical characteristics (tumour type, grade, peritumoral lymphocytes, MLH1, and p53 expression) can assist in prescreening for POLE exonuclease domain mutations in EC, increasing the probability of a mutation being detected from 7% to 33%.
|
28795426 |
2018 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A total of 460 endometrial cancers were stratified by ProMisE (Proactive Molecular Risk Classifier in Endometrial cancer) into 4 molecular subtypes: mismatch repair-deficient (MMRd), <i>POLE</i> mutant (POLE), p53 abnormal (p53abn), and p53 wild-type (p53wt).
|
30523022 |
2019 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
A total of 56 frozen tissues, which included 14 normal endometria, 13 endometrial hyperplasias (10 without atypia and 3 with atypia), and 29 endometrial carcinomas, were examined for the expression of Bax, Bcl-2, and p53 using immunohistochemistry.
|
12217750 |
2002 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Abnormal DNA ploidy status did correlate with the molecular subgroups of EC; abnormal DNA content was seen in the large majority of p53 abn cases.
|
28647100 |
2017 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Absence of p53 expression appears to be associated with concurrent endometrial carcinoma.
|
10785470 |
2000 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
According to The Cancer Genome Atlas classification, we distributed 95% of the undifferentiated carcinomas in this series as follows: (a) hypermutated tumors with loss of any mismatch repair protein expression and microsatellite instability (eight cases, 45%); (b) ultramutated carcinomas carrying mutations in the exonuclease domain of POLE (two cases, 11%); (c) high copy number alterations (copy-number high) tumors group exhibiting only TP53 mutations and high number of alterations detected by FISH (two cases, 11%); and (d) low copy number alterations (copy-number low) tumors with molecular alterations typical of endometrioid endometrial carcinomas (five cases, 28%).
|
27491810 |
2016 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Adding PTEN/TP53 mutation testing to BHLHE22/CDO1-based methylation testing did not improve the detection of endometrial cancer.
|
31779688 |
2019 |
|
Endometrial Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
|
10656459 |
2000 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus.
|
1913680 |
1991 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Also, 18 cases (20%) showed positive staining for p53. p53 staining was largely found in grade 3 (G3) endometrioid adenocarcinoma and other phenotypes of EC.
|
15583796 |
2005 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Alterations of the retinoblastoma (Rb) gene were evaluated in nine primary endometrial adenocarcinomas that we had previously analyzed for the presence of Ki-ras activations and p53 alterations and in three endometrial carcinoma cell lines.
|
8105795 |
1993 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although the majority of p53 wt endometrial carcinomas are grade 1 to 2 EC (sensitivity: 90%), fewer than half of grade 1 to 2 EC fell into the p53 wt category (positive predictive value: 42%).
|
28079598 |
2017 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.
|
20878066 |
2010 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Among p53 wt/NSMP EC, L1CAM remained a significant prognosticator for disease-specific survival after multivariate analysis (p = 0.035).
|
30050154 |
2018 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Among all polymorphisms analysed, an insertional variant in p53 (P53PIN3) and two polymorphisms in the 3'-end and exon 7 of CYP1A1 showed significant association with enhanced endometrial cancer risk.
|
9155064 |
1997 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Analysis of chromosome 10 aberrations in rat endometrial cancer-evidence for a tumor suppressor locus distal to Tp53.
|
17245700 |
2007 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
As 100% (7/7) of serous EC and 3% (2/59) of the LGECs showed mutant-pattern p53 staining, histotype may serve as a surrogate for p53 assessment, such that only HGEC or ambiguous carcinomas should be routinely subjected to p53 immunostaining.
|
31569187 |
2019 |
|
Endometrial Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects.
|
15723718 |
2005 |